Hosted on MSN

2026’s IPO lineup is getting dangerous

Something big is lining up for 2026, and it’s not just another IPO cycle. Wall Street is staring at one of the most crowded public-market queues in years, with 190+ companies racing toward the exit at ...
Pharmaceutical Technology on MSN

Aktis Oncology kicks 2026 IPO cycle off with $210m target

According to the registration form, Aktis intends to use a large portion of the IPO proceeds on the two programmes. Around ...

SEBI’s DRHP Reform Is A Start, But Disclosure Quality Still Falls Short For Retail Investors

It is in this context that SEBI’s December Board decision on Draft Red Herring Prospectuses (DRHPs) merits close examination.